BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31464927)

  • 1. Apatinib as an optional treatment in metastatic colorectal cancer.
    Li A; Wang K; Xu A; Wang G; Miao Y; Sun Z; Zhang J
    Medicine (Baltimore); 2019 Aug; 98(35):e16919. PubMed ID: 31464927
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical response and safety of apatinib monotherapy in recurrent, metastatic cervical cancer after failure of chemotherapy: a retrospective study.
    Xiao Y; Cheng H; Wang L; Yu X
    J Gynecol Oncol; 2020 Jan; 31(1):e2. PubMed ID: 31788992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study.
    Gou M; Si H; Zhang Y; Qian N; Wang Z; Shi W; Dai G
    Sci Rep; 2018 Mar; 8(1):4602. PubMed ID: 29545575
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Pilot Study of Apatinib as Third-Line Treatment in Patients With Heavily Treated Metastatic Colorectal Cancer.
    Liang L; Wang L; Zhu P; Xia Y; Qiao Y; Wu J; Zhuang W; Fei J; Wen Y; Jiang X
    Clin Colorectal Cancer; 2018 Sep; 17(3):e443-e449. PubMed ID: 29576426
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of apatinib in patients with advanced nonsmall cell lung cancer that failed prior chemotherapy or EGFR-TKIs: A pooled analysis.
    Ma JT; Sun J; Sun L; Zhang SL; Huang LT; Han CB
    Medicine (Baltimore); 2018 Aug; 97(35):e12083. PubMed ID: 30170427
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical Efficacy and Safety of Apatinib for the Treatment of Patients with Metastatic, Recurrent Cervical Cancer after Failure of Radiotherapy and First-Line Chemotherapy: A Prospective Study.
    Xia X; Jiang W; Qi W; Hong B; Zhao W
    Oncol Res Treat; 2020; 43(12):649-655. PubMed ID: 33045704
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apatinib for advanced nonsmall-cell lung cancer: A retrospective case series analysis.
    Yang C; Feng W; Wu D
    J Cancer Res Ther; 2018 Jan; 14(1):159-162. PubMed ID: 29516980
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and toxicity of apatinib combined with or without chemotherapy for patients with advanced or metastatic chemotherapy-refractory gastric adenocarcinoma: A prospective clinical study.
    Guo Y; Tang J; Huang XE; Cao J
    Medicine (Baltimore); 2019 Feb; 98(6):e13908. PubMed ID: 30732125
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Apatinib Monotherapy for Chemotherapy-Refractory Metastatic Colorectal Cancer: A Multi-centre, Single-Arm, Prospective Study.
    Wang F; Yuan X; Jia J; Bi X; Zhou Z; Zhou Q; Li X; Luo C; Deng M; Yi L; Li Y; Lu J; Su W; Chen H; Zhu Y; Wang S
    Sci Rep; 2020 Apr; 10(1):6058. PubMed ID: 32269247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II study of apatinib, a novel tyrosine kinase inhibitor targeting tumor angiogenesis, as second-line treatment for recurrent or advanced cervical cancer patients.
    Zhang L; Chen L; Yu H
    Invest New Drugs; 2020 Aug; 38(4):1186-1191. PubMed ID: 31637668
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apatinib in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: A Phase II, Open-Label, Single-Arm, Prospective Study.
    Ma X; Li L; Zhang L; Fu X; Li X; Wang X; Wu J; Sun Z; Zhang X; Feng X; Chang Y; Zhou Z; Nan F; Zhang J; Li Z; Zhang M
    Drug Des Devel Ther; 2020; 14():275-284. PubMed ID: 32158186
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Retrospective Cohort Study Evaluates Clinical Value of Anlotinib in Persistent, Metastatic, or Recurrent Cervical Cancer After Failure of First-Line Therapy.
    Yang H; Sun S; Mei Z; Xiang Q; Yang C; Chen M; Xie C; Zhou Y; Qiu H
    Drug Des Devel Ther; 2021; 15():4665-4674. PubMed ID: 34815663
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Apatinib Monotherapy or Combination Therapy for Non-Small Cell Lung Cancer Patients With Brain Metastases.
    Xu J; Liu X; Yang S; Shi Y
    Oncol Res; 2020 Mar; 28(2):127-133. PubMed ID: 31610827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial.
    Liu J; Liu Q; Li Y; Li Q; Su F; Yao H; Su S; Wang Q; Jin L; Wang Y; Lau WY; Jiang Z; Song E
    J Immunother Cancer; 2020 May; 8(1):. PubMed ID: 32448804
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer.
    Hu X; Cao J; Hu W; Wu C; Pan Y; Cai L; Tong Z; Wang S; Li J; Wang Z; Wang B; Chen X; Yu H
    BMC Cancer; 2014 Nov; 14():820. PubMed ID: 25376790
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy of apatinib combined with FOLFIRI in the first-line treatment of patients with metastatic colorectal cancer.
    Rong X; Liu H; Yu H; Zhao J; Wang J; Wang Y
    Invest New Drugs; 2022 Apr; 40(2):340-348. PubMed ID: 34997351
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction.
    Li J; Qin S; Xu J; Xiong J; Wu C; Bai Y; Liu W; Tong J; Liu Y; Xu R; Wang Z; Wang Q; Ouyang X; Yang Y; Ba Y; Liang J; Lin X; Luo D; Zheng R; Wang X; Sun G; Wang L; Zheng L; Guo H; Wu J; Xu N; Yang J; Zhang H; Cheng Y; Wang N; Chen L; Fan Z; Sun P; Yu H
    J Clin Oncol; 2016 May; 34(13):1448-54. PubMed ID: 26884585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Single-Arm, Phase II Study of Apatinib in Refractory Metastatic Colorectal Cancer.
    Chen X; Qiu T; Zhu Y; Sun J; Li P; Wang B; Lin P; Cai X; Han X; Zhao F; Shu Y; Chang L; Jiang H; Gu Y
    Oncologist; 2019 Jul; 24(7):883-e407. PubMed ID: 30877190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II study of apatinib in patients with recurrent epithelial ovarian cancer.
    Miao M; Deng G; Luo S; Zhou J; Chen L; Yang J; He J; Li J; Yao J; Tan S; Tang J
    Gynecol Oncol; 2018 Feb; 148(2):286-290. PubMed ID: 29248198
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment.
    Lin Y; Wu Z; Zhang J; Hu X; Wang Z; Wang B; Cao J; Wang L
    Tumour Biol; 2017 Jun; 39(6):1010428317711033. PubMed ID: 28639910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.